Asset Details
Do you wish to reserve the book?
Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
Do you wish to request the book?
Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
2021
Overview
Background
Giant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab.
Methods
This analysis was conducted on patients with pathologically confirmed GCTB and measurable active disease treated with denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on study days 8 and 15, as part of a phase 2, open-label, multicenter study. We identified potential cases of malignancy related to GCTB through an independent multidisciplinary review or medical history, associated imaging or histopathologic reports, and disease course. The findings were summarized and no statistical analysis was performed.
Results
Twenty of five hundred twenty-six patients (3.8%) who received at least one dose of denosumab were misdiagnosed with GCTB that was later discovered to be malignancies: five primary malignant GCTB, five secondary malignant GCTB, four sarcomatous transformations, and six patients with other malignancies (giant cell-rich osteosarcoma, undifferentiated pleomorphic sarcoma, spindle cell sarcoma, osteogenic sarcoma, phosphaturic mesenchymal tumor of mixed connective tissue type, and fibrosarcoma/malignant fibrous histiocytoma). Many malignancies were present before denosumab was initiated (8 definitive cases, 7 likely cases), excluding potential involvement of denosumab in these cases. Signs associated with potential misdiagnoses of GCTB included poor mineralization with denosumab treatment, rapid relapse in pain, or a failure of the typical dramatic improvement in pain normally observed with denosumab.
Conclusions
Although rare, GCTB can undergo malignant transformation, and rates in this study were consistent with previous reports. Signs of poor mineralization or lack of response to denosumab treatment may warrant close monitoring.
Trial registration
clinicaltrials.gov
, (
NCT00680992
). Registered May 20, 2008.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adult
/ Age
/ Aged
/ Biomarkers, Tumor - analysis
/ Biomedical and Life Sciences
/ Biopsy
/ Bone Density Conservation Agents - therapeutic use
/ Bone Neoplasms - drug therapy
/ Cysts
/ Female
/ Giant Cell Tumor of Bone - drug therapy
/ Giant Cell Tumor of Bone - metabolism
/ Giant Cell Tumor of Bone - pathology
/ Health Promotion and Disease Prevention
/ Humans
/ Male
/ Medical and radiation oncology
/ Oncology
/ Pain
/ Patients
/ Sarcoma
